[89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma
[89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma
复制标题
[89Zr]Zr-huJ591 免疫 PET 靶向 IDH 突变型间变性少突胶质细胞瘤中的 PSMA
DOI：
10.1007/s00259-021-05543-5
复制
发表时间：
2021
影响因子：
9.1
通讯作者：
J. Osborne
中科院分区：
文献类型：
--
作者：
S. Krebs;C. Grommes;M. McDevitt;S. Carlin;J. O’Donoghue;M. Graham;R. Young;H. Schöder;P. Gutin;N. Bander;J. Osborne
Prostate-specific membrane antigen (PSMA)-targeted PET has shown strong potential for localizing metastatic prostate cancer, as we have shown with [89Zr] Zr-huJ591 immuno-PET [1, 2]. PSMA is also expressed in the tumor neovasculature of various other solid tumors including glioblastoma [3, 4], but has not yet been described in isocitrate dehydrogenase (IDH) mutant lower-grade glioma (LGG, WHO grade II, III). Here, we report the case of a 51-year-old woman diagnosed 8.5 years ago with grade II oligodendroglioma (1p/19q co-deleted, IDH mutant) who was referred for [89Zr] Zr-huJ591 PET two days after MRI performed with intravenously injected gadopentetate dimeglumine (Magnevist; Bayer HealthCare Pharmaceuticals, Wayne, NJ) revealed concern for disease progression despite multiple prior treatments including surgery and chemoradiation, most recently with IDH inhibitor AG-120 (NCT02074839). Cold antibody huJ591 (23.5 mg) was injected intravenously over five minutes followed by 182.04 MBq/1.5 mg of [89Zr] Zr-huJ591 injected intravenously over one minute. Serial PET performed at days1, 2, and 6 post-injection, fused with axial post-contrast T1-weighted MRI, demonstrated a nodular enhancing lesion anterior inferior to the resection cavity within the left medial postcentral gyrus and nodular enhancing lesions with heterogenous uptake in the left temporooccipital lobe (a–c). Incidentally, uptake in a probable hemangioma in the right parietal bone (b, blue arrow) was observed. The patient underwent resection of both lesions post-imaging; histology of both lesions showed anaplastic oligodendroglioma (grade III). IDH mutant LGG mainly occurs in young adults. Unmet needs for this population include identifying the optimal timing of treatment initiation and choice of treatment regimen.[89Zr] Zr-huJ591 PET offers quantitative visualization of PSMA expression in neovasculature, prospective dosimetry for huJ591-based radioimmunotherapy supported by serial imaging over multiple days, and assessment of response to radiolabeled J591 and other anti-angiogenic agents. In view of the persistent and/or continuously rising lesional tracer accumulation in this patient, longer post-injection imaging periods are indicated in future studies, particularly for optimized dosimetric calculations. Preliminary
